학술논문

The Global Phosphorylation Landscape of SARS-CoV-2 Infection
Document Type
article
Source
Cell. 182(3)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Biological Sciences
Infectious Diseases
Lung
Vaccine Related
Emerging Infectious Diseases
Biodefense
Prevention
Infection
Good Health and Well Being
A549 Cells
Angiotensin-Converting Enzyme 2
Animals
Antiviral Agents
Betacoronavirus
COVID-19
Caco-2 Cells
Casein Kinase II
Chlorocebus aethiops
Coronavirus Infections
Cyclin-Dependent Kinases
Drug Evaluation
Preclinical
HEK293 Cells
Host-Pathogen Interactions
Humans
Pandemics
Peptidyl-Dipeptidase A
Phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphorylation
Pneumonia
Viral
Protein Kinase Inhibitors
Proteomics
Proto-Oncogene Proteins
Receptor Protein-Tyrosine Kinases
SARS-CoV-2
Spike Glycoprotein
Coronavirus
Vero Cells
p38 Mitogen-Activated Protein Kinases
Axl Receptor Tyrosine Kinase
AXL
CDK
MAPK
PIKFYVE
antiviral
casein kinase II
mass spectrometry
p38
phosphoproteomics
Medical and Health Sciences
Developmental Biology
Biological sciences
Biomedical and clinical sciences
Language
Abstract
The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies. Here we present a quantitative mass spectrometry-based phosphoproteomics survey of SARS-CoV-2 infection in Vero E6 cells, revealing dramatic rewiring of phosphorylation on host and viral proteins. SARS-CoV-2 infection promoted casein kinase II (CK2) and p38 MAPK activation, production of diverse cytokines, and shutdown of mitotic kinases, resulting in cell cycle arrest. Infection also stimulated a marked induction of CK2-containing filopodial protrusions possessing budding viral particles. Eighty-seven drugs and compounds were identified by mapping global phosphorylation profiles to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.